desoxycorticosterone acetate has been researched along with Fibrosis in 28 studies
Desoxycorticosterone Acetate: The 21-acetate derivative of desoxycorticosterone.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fibrosis is a hallmark of chronic hypertension and disrupts the viability of human bone marrow-derived mesenchymal stromal cells (BM-MSCs) post-transplantation." | 5.91 | Simultaneous late-gadolinium enhancement and T1 mapping of fibrosis and a novel cell-based combination therapy in hypertensive mice. ( Broughton, BRS; de Veer, M; Li, Y; Ricardo, SD; Salimova, E; Samuel, CS; Zheng, G, 2023) |
| "To explore the role of imatinib in desoxycorticosterone acetate (DOCA)-induced myocardial fibrosis in rats by the p38 mitogen-activated protein kinase (MAPK) signaling pathway." | 3.96 | Effect of imatinib on DOCA-induced myocardial fibrosis in rats through P38 MAPK signaling pathway. ( Bu, XH; Chen, DF; Dong, B; Qin, HB; Xi, Y, 2020) |
| "DOCA-salt was characterized by increased blood pressure, decreased renal function, increased proteinuria, increased glomerulosclerosis and tubulointerstitial fibrosis with myofibroblast accumulation, increased renal endothelin-1 levels and RhoA activity along with increased expression of connective tissue growth factor at both mRNA and protein levels as compared with uninephrectomized control male Wistar rats." | 3.80 | Endothelin receptor blockade ameliorates renal injury by inhibition of RhoA/Rho-kinase signalling in deoxycorticosterone acetate-salt hypertensive rats. ( Chang, NC; Chung, TH; Lee, TM; Lin, SZ, 2014) |
| "Fibrosis is a hallmark of chronic hypertension and disrupts the viability of human bone marrow-derived mesenchymal stromal cells (BM-MSCs) post-transplantation." | 1.91 | Simultaneous late-gadolinium enhancement and T1 mapping of fibrosis and a novel cell-based combination therapy in hypertensive mice. ( Broughton, BRS; de Veer, M; Li, Y; Ricardo, SD; Salimova, E; Samuel, CS; Zheng, G, 2023) |
| "Cardiac fibrosis was induced in male Sprague Dawley rats by uninephrectomy and by subsequent administration of deoxycorticosterone acetate (DOCA) every 4th day till 28 days along with 1% NaCl in drinking water." | 1.91 | Repositioning Glibenclamide in cardiac fibrosis by targeting TGF-β1-pSmad2/3-NLRP3 cascade. ( Chandel, A; Gandhi, T; Gupta, D; Pandya, H; Patel, A, 2023) |
| "Calcitriol treatment attenuated FGF23-induced cardiac fibrosis and improved diastolic function via inhibition of transforming growth factor-β signaling." | 1.91 | Fibroblast Growth Factor 23 Exacerbates Cardiac Fibrosis in Deoxycorticosterone Acetate-Salt Mice With Hypertension. ( Honda, H; Kato, T; Koiwa, F; Mizobuchi, M; Ogata, H; Saito, T, 2023) |
| "Hypertension was induced by deoxycorticosterone acetate (DOCA)-salt administration in uninephrectomized rats for 6 weeks." | 1.51 | Activation of Liver X Receptors by GW3965 Attenuated Deoxycorticosterone Acetate-Salt Hypertension-Induced Cardiac Functional and Structural Changes. ( Bal, NB; Demirel-Yilmaz, E; Han, S; Kiremitci, S; Sadi, G; Uludag, O; Usanmaz, SE, 2019) |
| "Hypertension was induced by deoxycorticosterone-acetate (DOCA) and salt administration in uni-nephrectomized rats for 12 weeks." | 1.51 | Hypertension-induced cardiac impairment is reversed by the inhibition of endoplasmic reticulum stress. ( Bal, NB; Demirel-Yilmaz, E; Han, S; Kiremitci, S; Sadi, G; Uludag, O, 2019) |
| "Obesity and hypertension are prevalent comorbidities in heart failure with preserved ejection fraction." | 1.51 | Limited synergy of obesity and hypertension, prevalent risk factors in onset and progression of heart failure with preserved ejection fraction. ( Brandt, MM; Cheng, C; Cramer, MJ; Duncker, DJ; Joles, JA; Krebber, MM; Mokry, M; Nguyen, ITN; van de Wouw, J; Verhaar, MC, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (53.57) | 24.3611 |
| 2020's | 13 (46.43) | 2.80 |
| Authors | Studies |
|---|---|
| Toba, H | 1 |
| Ikemoto, MJ | 1 |
| Kobara, M | 1 |
| Nakata, T | 1 |
| Luettges, K | 1 |
| Bode, M | 1 |
| Diemer, JN | 1 |
| Schwanbeck, J | 1 |
| Wirth, EK | 1 |
| Klopfleisch, R | 1 |
| Kappert, K | 1 |
| Thiele, A | 1 |
| Ritter, D | 1 |
| Foryst-Ludwig, A | 1 |
| Kolkhof, P | 1 |
| Wenzel, UO | 1 |
| Kintscher, U | 1 |
| Wu, H | 2 |
| Tang, LX | 2 |
| Wang, XM | 2 |
| Li, LP | 2 |
| Chen, XK | 2 |
| He, YJ | 2 |
| Yang, DZ | 2 |
| Shi, Y | 2 |
| Shou, JL | 2 |
| Zhang, ZS | 2 |
| Wang, L | 2 |
| Lu, BJ | 2 |
| An, SM | 2 |
| Zeng, CY | 2 |
| Wang, WE | 2 |
| Li, Y | 2 |
| Zheng, G | 2 |
| Salimova, E | 2 |
| Broughton, BRS | 2 |
| Ricardo, SD | 2 |
| de Veer, M | 2 |
| Samuel, CS | 4 |
| Wu, JC | 1 |
| Wang, XJ | 1 |
| Zhu, JH | 1 |
| Huang, XY | 1 |
| Liu, M | 1 |
| Qiao, Z | 1 |
| Zhang, Y | 1 |
| Sun, Y | 1 |
| Wang, ZY | 1 |
| Zhan, P | 1 |
| Zhang, T | 1 |
| Hu, HL | 1 |
| Liu, H | 1 |
| Tang, W | 1 |
| Yi, F | 1 |
| Gandhi, T | 1 |
| Patel, A | 1 |
| Gupta, D | 1 |
| Pandya, H | 1 |
| Chandel, A | 1 |
| Saito, T | 1 |
| Mizobuchi, M | 1 |
| Kato, T | 1 |
| Ogata, H | 1 |
| Koiwa, F | 1 |
| Honda, H | 1 |
| Gao, Y | 2 |
| Liu, B | 2 |
| Guo, X | 1 |
| Nie, J | 2 |
| Zou, H | 1 |
| Wen, S | 2 |
| Yu, W | 2 |
| Liang, H | 2 |
| Song, J | 1 |
| Cui, Z | 1 |
| Bal, NB | 2 |
| Han, S | 2 |
| Usanmaz, SE | 1 |
| Kiremitci, S | 2 |
| Sadi, G | 2 |
| Uludag, O | 2 |
| Demirel-Yilmaz, E | 2 |
| Cao, HJ | 1 |
| Fang, J | 1 |
| Zhang, YL | 1 |
| Zou, LX | 1 |
| Han, X | 1 |
| Yang, J | 1 |
| Yan, X | 1 |
| Li, PB | 1 |
| Wang, HX | 2 |
| Guo, SB | 1 |
| Li, HH | 2 |
| Omarjee, L | 1 |
| Roy, C | 1 |
| Leboeuf, C | 1 |
| Favre, J | 1 |
| Henrion, D | 1 |
| Mahe, G | 1 |
| Leftheriotis, G | 1 |
| Martin, L | 1 |
| Janin, A | 1 |
| Kauffenstein, G | 1 |
| Wu, Y | 2 |
| An, C | 1 |
| Jin, X | 1 |
| Hu, Z | 1 |
| Wang, Y | 1 |
| Dong, B | 1 |
| Chen, DF | 1 |
| Bu, XH | 1 |
| Qin, HB | 1 |
| Xi, Y | 1 |
| Lyu, B | 1 |
| Wang, W | 1 |
| Ji, XY | 1 |
| Ritter, JK | 1 |
| Li, N | 1 |
| Yan, W | 1 |
| Bi, HL | 1 |
| Liu, LX | 1 |
| Li, NN | 1 |
| Liu, Y | 1 |
| Du, J | 1 |
| Tian, M | 1 |
| Tang, L | 1 |
| Beddhu, S | 1 |
| Huang, Y | 1 |
| Chen, S | 1 |
| Cai, H | 1 |
| Krishnan, SM | 2 |
| Ling, YH | 2 |
| Huuskes, BM | 1 |
| Ferens, DM | 1 |
| Saini, N | 1 |
| Chan, CT | 2 |
| Diep, H | 2 |
| Kett, MM | 1 |
| Kemp-Harper, BK | 2 |
| Robertson, AAB | 1 |
| Cooper, MA | 1 |
| Peter, K | 1 |
| Latz, E | 2 |
| Mansell, AS | 1 |
| Sobey, CG | 2 |
| Drummond, GR | 2 |
| Vinh, A | 1 |
| Brandt, MM | 1 |
| Nguyen, ITN | 1 |
| Krebber, MM | 1 |
| van de Wouw, J | 1 |
| Mokry, M | 1 |
| Cramer, MJ | 1 |
| Duncker, DJ | 1 |
| Verhaar, MC | 1 |
| Joles, JA | 1 |
| Cheng, C | 1 |
| Kee, HJ | 1 |
| Bae, EH | 1 |
| Park, S | 1 |
| Lee, KE | 1 |
| Suh, SH | 1 |
| Kim, SW | 1 |
| Jeong, MH | 1 |
| Lee, TM | 1 |
| Chung, TH | 1 |
| Lin, SZ | 1 |
| Chang, NC | 1 |
| Liu, CT | 1 |
| Chien, SP | 1 |
| Hsu, DZ | 1 |
| Periasamy, S | 1 |
| Liu, MY | 1 |
| Marques, FZ | 1 |
| Nelson, E | 1 |
| Chu, PY | 1 |
| Horlock, D | 1 |
| Fiedler, A | 1 |
| Ziemann, M | 1 |
| Tan, JK | 1 |
| Kuruppu, S | 1 |
| Rajapakse, NW | 1 |
| El-Osta, A | 1 |
| Mackay, CR | 1 |
| Kaye, DM | 1 |
| Ferens, D | 1 |
| Chin-Dusting, J | 1 |
| Hewitson, TD | 1 |
| Mansell, A | 1 |
| Sun, SJ | 1 |
| Yao, JL | 1 |
| Xu, LB | 1 |
| Rui, Q | 1 |
| Zhang, NN | 1 |
| Chen, M | 1 |
| Jiang, YF | 1 |
| Yang, HJ | 1 |
| Zhou, YF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Innovative Natural Dietary Formulation on Primary Hypertension and the Underlying Mechanism of Gut Microbiome Restoration: Pilot Study[NCT04403347] | Early Phase 1 | 90 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
28 other studies available for desoxycorticosterone acetate and Fibrosis
| Article | Year |
|---|---|
Secreted protein acidic and rich in cysteine (SPARC) and a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS1) increments by the renin-angiotensin system induce renal fibrosis in deoxycorticosterone acetate-salt hypertensive rats.
Topics: ADAMTS1 Protein; Angiotensin II Type 1 Receptor Blockers; Animals; Desoxycorticosterone Acetate; Ext | 2022 |
Finerenone Reduces Renal RORγt γδ T Cells and Protects against Cardiorenal Damage.
Topics: Animals; Blood Pressure; Desoxycorticosterone Acetate; Fibrosis; Hypertension; Hypertension, Renal; | 2022 |
Porcupine inhibitor CGX1321 alleviates heart failure with preserved ejection fraction in mice by blocking WNT signaling.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Desoxycorticosterone Acetate; Fibrosis; Heart Failure; Mice | 2023 |
Porcupine inhibitor CGX1321 alleviates heart failure with preserved ejection fraction in mice by blocking WNT signaling.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Desoxycorticosterone Acetate; Fibrosis; Heart Failure; Mice | 2023 |
Porcupine inhibitor CGX1321 alleviates heart failure with preserved ejection fraction in mice by blocking WNT signaling.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Desoxycorticosterone Acetate; Fibrosis; Heart Failure; Mice | 2023 |
Porcupine inhibitor CGX1321 alleviates heart failure with preserved ejection fraction in mice by blocking WNT signaling.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Desoxycorticosterone Acetate; Fibrosis; Heart Failure; Mice | 2023 |
Simultaneous late-gadolinium enhancement and T1 mapping of fibrosis and a novel cell-based combination therapy in hypertensive mice.
Topics: Animals; Contrast Media; Desoxycorticosterone Acetate; Fibrosis; Gadolinium; Humans; Hypertension; M | 2023 |
Simultaneous late-gadolinium enhancement and T1 mapping of fibrosis and a novel cell-based combination therapy in hypertensive mice.
Topics: Animals; Contrast Media; Desoxycorticosterone Acetate; Fibrosis; Gadolinium; Humans; Hypertension; M | 2023 |
Simultaneous late-gadolinium enhancement and T1 mapping of fibrosis and a novel cell-based combination therapy in hypertensive mice.
Topics: Animals; Contrast Media; Desoxycorticosterone Acetate; Fibrosis; Gadolinium; Humans; Hypertension; M | 2023 |
Simultaneous late-gadolinium enhancement and T1 mapping of fibrosis and a novel cell-based combination therapy in hypertensive mice.
Topics: Animals; Contrast Media; Desoxycorticosterone Acetate; Fibrosis; Gadolinium; Humans; Hypertension; M | 2023 |
GPR97 deficiency ameliorates renal interstitial fibrosis in mouse hypertensive nephropathy.
Topics: Animals; Desoxycorticosterone Acetate; Fibrosis; Hypertension; Hypertension, Renal; Kidney; Mice; Tr | 2023 |
Repositioning Glibenclamide in cardiac fibrosis by targeting TGF-β1-pSmad2/3-NLRP3 cascade.
Topics: Animals; Desoxycorticosterone Acetate; Fibrosis; Glyburide; Inflammasomes; Male; NLR Family, Pyrin D | 2023 |
Fibroblast Growth Factor 23 Exacerbates Cardiac Fibrosis in Deoxycorticosterone Acetate-Salt Mice With Hypertension.
Topics: Animals; Blood Pressure; Calcitriol; Desoxycorticosterone Acetate; Fibroblast Growth Factor-23; Fibr | 2023 |
Interferon regulatory factor 4 deletion protects against kidney inflammation and fibrosis in deoxycorticosterone acetate/salt hypertension.
Topics: Acetates; Animals; Blood Pressure; Desoxycorticosterone; Desoxycorticosterone Acetate; Fibrosis; Hyp | 2023 |
JMJD3 ablation in myeloid cells confers renoprotection in mice with DOCA/salt-induced hypertension.
Topics: Animals; Blood Pressure; Desoxycorticosterone; Desoxycorticosterone Acetate; Fibrosis; Hypertension; | 2023 |
Interferon regulatory factor 4 deletion protects against kidney inflammation and fibrosis in deoxycorticosterone acetate/salt hypertension: Erratum.
Topics: Acetates; Blood Pressure; Desoxycorticosterone; Desoxycorticosterone Acetate; Fibrosis; Humans; Hype | 2023 |
Activation of Liver X Receptors by GW3965 Attenuated Deoxycorticosterone Acetate-Salt Hypertension-Induced Cardiac Functional and Structural Changes.
Topics: Animals; Apoptosis; Benzoates; Benzylamines; Blood Pressure; Desoxycorticosterone Acetate; Disease M | 2019 |
Hypertension-induced cardiac impairment is reversed by the inhibition of endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Blood Pressure; Calcium; Desoxycorticosterone Acetate; Disease Models, Animal; E | 2019 |
Genetic ablation and pharmacological inhibition of immunosubunit β5i attenuates cardiac remodeling in deoxycorticosterone-acetate (DOCA)-salt hypertensive mice.
Topics: Animals; Cardiomegaly; Chymotrypsin; Desoxycorticosterone Acetate; Fibrosis; Hypertension; Inflammat | 2019 |
Evidence of Cardiovascular Calcification and Fibrosis in Pseudoxanthoma Elasticum Mouse Models Subjected to DOCA-Salt Hypertension.
Topics: Animals; Calcinosis; Calcium; Cardiovascular System; Desoxycorticosterone Acetate; Fibrosis; Hyperte | 2019 |
Disruption of CXCR6 Ameliorates Kidney Inflammation and Fibrosis in Deoxycorticosterone Acetate/Salt Hypertension.
Topics: Animals; Blood Pressure; Desoxycorticosterone Acetate; Extracellular Matrix Proteins; Fibroblasts; F | 2020 |
Effect of imatinib on DOCA-induced myocardial fibrosis in rats through P38 MAPK signaling pathway.
Topics: Animals; Desoxycorticosterone Acetate; Fibrosis; Imatinib Mesylate; Male; Myocardium; p38 Mitogen-Ac | 2020 |
Detrimental role of sphingosine kinase 1 in kidney damage in DOCA-salt hypertensive model: evidence from knockout mice.
Topics: Actins; Albuminuria; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blotting, Wes | 2020 |
Knockout of immunoproteasome subunit β2i ameliorates cardiac fibrosis and inflammation in DOCA/Salt hypertensive mice.
Topics: Animals; Cysteine Endopeptidases; Desoxycorticosterone Acetate; Fibrosis; Hypertension; Inflammation | 2017 |
Adiponectin attenuates kidney injury and fibrosis in deoxycorticosterone acetate-salt and angiotensin II-induced CKD mice.
Topics: Adiponectin; Angiotensin II; Animals; Cell Proliferation; Desoxycorticosterone Acetate; Disease Mode | 2018 |
Adiponection, a novel player to save the kidneys.
Topics: Acetates; Adiponectin; Angiotensin II; Animals; Desoxycorticosterone Acetate; Fibrosis; Mice; Renal | 2018 |
Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Blood Pressure; Chemotaxis, | 2019 |
Limited synergy of obesity and hypertension, prevalent risk factors in onset and progression of heart failure with preserved ejection fraction.
Topics: Animals; Apoptosis; Capillaries; Desoxycorticosterone Acetate; Disease Progression; Fatty Acids; Fib | 2019 |
HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6/HDAC8 enzyme activity.
Topics: Animals; Cardiomegaly; Desoxycorticosterone Acetate; Disease Models, Animal; Enzyme Activation; Fibr | 2013 |
Endothelin receptor blockade ameliorates renal injury by inhibition of RhoA/Rho-kinase signalling in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Animals; Atrasentan; Blood Pressure; Desoxycorticosterone Acetate; Endothelin Receptor Antagonists; | 2014 |
Curative effect of sesame oil in a rat model of chronic kidney disease.
Topics: Albuminuria; Animals; Antioxidants; Collagen; Desoxycorticosterone Acetate; Disease Models, Animal; | 2015 |
High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice.
Topics: Animals; Bacteria; Blood Pressure; Desoxycorticosterone Acetate; Dietary Fiber; Dietary Supplements; | 2017 |
Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension.
Topics: Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Desoxycorticosterone Acetate; Fibrosis | 2017 |
Cardiac structural remodeling in hypertensive cardiomyopathy.
Topics: Animals; Cardiomyopathies; Desoxycorticosterone Acetate; Diet, High-Fat; Echocardiography; Female; F | 2017 |